IDXX - Insider Decision: Jonathan Jay Mazelsky Exercises Options At IDEXX Laboratories For $5.93M | Benzinga
On December 6, it was revealed in an SEC filing that Jonathan Jay Mazelsky, President and CEO at IDEXX Laboratories (NASDAQ:IDXX) executed a significant exercise of company stock options.
What Happened: A notable Form 4 filing on Wednesday with the U.S. Securities and Exchange Commission revealed that Mazelsky, President and CEO at IDEXX Laboratories, exercised stock options for 13,424 shares of IDXX, resulting in a transaction value of $5,933,676.
During Thursday's morning session, IDEXX Laboratories shares down by 0.0%, currently priced at $521.56. Considering the current price, Mazelsky's 13,424 shares have a total value of $5,933,676.
Unveiling the Story Behind IDEXX Laboratories
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.
Key Indicators: IDEXX Laboratories's Financial Health
Revenue Growth: IDEXX Laboratories's remarkable performance in 3 months is evident. ...